SEYLANMED
SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis. SeylanMED is committed to the development of a topical Akt inhibitor as a first in class treatment for Seborrheic Keratosis (SK). Our lead drug candidate, SM-020, is the first molecularly-targeted approach for the treatment of SK. SeylanMED is funded by angel investors including board-certified dermatologists.
SEYLANMED
Industry:
Biotechnology Life Science Wellness
Founded:
2016-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.seylanmed.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1.17 M USD
Technology used in webpage:
Domain Not Resolving PHP
Current Employees Featured
